Marvel Biosciences Corp (MRVL) Price & Analysis

Compare

39 Followers

MRVL Stock Chart & Stats

C$0.14

-C$0.01(-6.45%)

At close: Jan 08 4:00 PM EST

C$0.14

-C$0.01(-6.45%)

Day’s Range― - ―

52-Week RangeC$0.08 - C$0.40

Previous CloseN/A

Volume5.00K

Average Volume (3M)89.38K

Market Cap

C$7.54M

Enterprise ValueC$8.64M

Total Cash (Recent Filing)C$633.54K

Total Debt (Recent Filing)C$2.31M

Price to Earnings (P/E)―

Beta-0.14

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding58,004,482

10 Day Avg. Volume75,294

30 Day Avg. Volume89,378

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-2.07

Price to Sales (P/S)0.00

P/FCF Ratio-7.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Near-term Financing Via Warrant ExercisesHigh warrant exercise rates materially improve near-term cash availability and extend runway, reducing immediate refinancing pressure. That structural financing relief gives management time to advance R&D or seek partnerships, lowering short-term solvency risk over the next several months.

Cash Flow Closely Tracks Reported LossesOperating cash flow and free cash flow that align with accounting losses indicate earnings quality and transparent cash dynamics. This makes forecasting burn and planning financings more reliable, aiding management decisions and investor assessment of runway and funding needs over the medium term.

Modest Asset Increase Versus Prior Annual PeriodAn increase in total assets suggests some capitalization or investment into the business, which can support near-term operations or R&D activities. Gradual asset growth, if sustained, improves the tangible base and can modestly enhance credibility with partners and lenders over a 2-6 month horizon.

Bears Say

Negative Shareholders' EquityNegative equity means liabilities exceed assets, signaling a structurally stressed balance sheet. This limits access to non-dilutive financing, raises insolvency risk if cash deteriorates further, and forces dependence on equity issuance or dilutive instruments to fund operations over the medium term.

Persistent Negative Operating And Free Cash FlowSustained cash burn of roughly -1.07M TTM creates continuous funding requirements, shrinking runway absent new capital. For an R&D-stage biotech, this persistent outflow amplifies dilution and refinancing risk and constrains ability to progress costly development milestones without external support.

Pre-revenue With Sustained Operating And Net LossesA pre-revenue profile with recurring operating and net losses means intrinsic cash generation is absent and company value depends on future R&D success. Persistent losses increase execution risk and extend dependency on capital markets or partners for funding over the next several months.

Marvel Biosciences Corp News

Marvel Biosciences Grants Deferred Share Units to Independent Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) has issued an announcement. Marvel Biosciences Corp. has granted 50,001 deferred share...

8d ago

Marvel Biosciences Wins NRC IRAP Support for Pediatric Liquid Form of Lead Neurodrug

Marvel Biosciences Corp ( ($TSE:MRVL) ) has issued an announcement. Marvel Biosciences Corp. has secured advisory services and...

8d ago

Marvel Biosciences Wins Key Japanese Patent for Lead Neurology Drug MB-204

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an update. Marvel Biosciences Corp. has secured a Japanese composition-of-matter...

23d ago

Marvel Biosciences Issues Deferred Share Units to Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has announced the issuance of...

4M ago

Marvel Biosciences Accelerates Warrant Expiry Amid Strong Shareholder Confidence

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has announced the acceleration of...

5M ago

Marvel Biosciences Secures Chinese Patent for Lead Drug Candidate MB-204

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an announcement. Marvel Biosciences Corp. has been granted a Chinese...

6M ago

Marvel Biosciences Grants Deferred Share Units to Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an update. Marvel Biosciences Corp. has announced the grant of...

7M ago

Marvel Biosciences Completes $1 Million Private Placement to Advance Neurological Research

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has successfully closed a non-brokered...

10M ago

Marvel Biosciences Closes Second Tranche of Private Placement

An update from Marvel Biosciences Corp ( ($TSE:MRVL) ) is now available. Marvel Biosciences Corp. announced the closing...

10M ago

Marvel Biosciences’ MB-204 Shows Promising Results in Rett Syndrome Study

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. announced promising results from its...

10M ago

MRVL FAQ

What was Marvel Biosciences Corp’s price range in the past 12 months?

Marvel Biosciences Corp lowest stock price was C$0.07 and its highest was C$0.40 in the past 12 months.

What is Marvel Biosciences Corp’s market cap?

Marvel Biosciences Corp’s market cap is C$7.54M.

When is Marvel Biosciences Corp’s upcoming earnings report date?

Marvel Biosciences Corp’s upcoming earnings report date is Apr 01, 2026 which is in 34 days.

How were Marvel Biosciences Corp’s earnings last quarter?

Currently, no data Available

Is Marvel Biosciences Corp overvalued?

According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Marvel Biosciences Corp pay dividends?

Marvel Biosciences Corp does not currently pay dividends.

What is Marvel Biosciences Corp’s EPS estimate?

Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marvel Biosciences Corp have?

Marvel Biosciences Corp has 58,004,482 shares outstanding.

What happened to Marvel Biosciences Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Marvel Biosciences Corp?

Currently, no hedge funds are holding shares in TSE:MRVL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marvel Biosciences Corp

Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.